Skip to content
Medical Health Aged Care

New clinical trial to compare the effectiveness of IV treatments for severe asthma in children

Monash University 2 mins read

A clinical trial to determine the best intravenous (IV) treatments for children with severe asthma will go ahead thanks to an almost $5 million Medical Research Future Fund grant.

 

The clinical trial – spearheaded by Professor Simon Craig, Adjunct Clinical Professor in the School of Clinical Sciences at Monash Health and paediatric emergency medicine physician at Monash Medical Centre – will provide clinicians with clear evidence to make more informed decisions, provide faster and more effective treatment, reduce unnecessary variation between hospitals, and ultimately improve outcomes for children with severe asthma.

 

“Asthma is one of the most common reasons children come to emergency departments across Australia. Most children improve with standard treatments such as inhaled salbutamol and oral steroids, but a small group remain very unwell and are at risk of needing intensive care. For these children, doctors often use ‘second-line’ medicines given through a vein to help open the airways,” Professor Craig said. 

 

“The two most commonly used options in Australia are IV magnesium and IV aminophylline; however, we don't know which one works better. Practice varies between hospitals, and decisions are often based on tradition rather than strong evidence. Because both medicines have potential benefits and risks, families and clinicians need clear evidence to guide decisions.” 

 

This randomised controlled trial will directly compare the two treatments in children who need extra help beyond standard care. 

The research team aims to compare the two treatments in over 1,000 children aged from two to 15 years with acute asthma, across 18 hospitals throughout Australia and New Zealand, all part of the PREDICT network. 

 

“By measuring how quickly children improve, how long they stay in hospital, how often they need admission to intensive care, and what side effects occur, the study will provide the first strong, head-to-head evidence about which medicine gives the best balance of benefit and safety,” Professor Craig said. 

 

MEDIA ENQUIRIES 

Helena Powell

Media Advisor (medical), Monash University 

M: +61 474 444 171

E: [email protected] 

 

GENERAL MEDIA ENQUIRIES

Monash Media

T: +61 (0) 3 9903 4840

E: [email protected]

For more Monash media stories, visit our news and events site

More from this category

  • Medical Health Aged Care, Science
  • 22/01/2026
  • 08:00
La Trobe University

Drinking less could prevent thousands of cancer deaths, study shows

Reducing annual alcohol consumption in Australia by one litre a person could significantly lower deaths from several major cancers, particularly among older Australians, a new study led by La Trobe University has found. Using more than 70 years of national mortality, alcohol and tobacco consumption, and health-expenditure data, researchers examined how long-term population level alcohol consumption in Australia is associated with mortality from four alcohol-related cancers. Published in the British Journal of Cancer, the study said that long-term alcohol exposure was a causal factor in: Some 45 per cent of male upper aerodigestive tract (UADT) cancer deaths About 21 per…

  • Medical Health Aged Care
  • 22/01/2026
  • 03:41
Galderma

Galderma Provides Update on Arbitration Case Regarding Neuromodulator Research and Development Partnership

ZUG, Switzerland–BUSINESS WIRE– Galderma (SIX:GALD), the pure-play dermatology category leader, today announced that an International Chamber of Commerce arbitral tribunal issued an award confirming…

  • Contains:
  • Medical Health Aged Care
  • 21/01/2026
  • 20:10
Ramsay Health Care

St George Private Hospital begins $16.4m expansion to strengthen patient care

Key Facts: $16.4m expansion project at St George Private Hospital (Sydney) will add 2 fully equipped operating theatres plus 2 future theatre spaces Project…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.